\nbreast cancer, stages I through IIIA. The software returns a 0 to 100 score that places the patient
\nin a low, intermediate or high risk category for recurrence at five and ten years.<\/p>\n
![\"Three-dimensional](\"https:\/\/rtmedical.com.br\/wp-content\/uploads\/2026\/10\/rm-mama-risco-recidiva-ia.jpg\")
What spatial modelling adds to pathology<\/h2>\n
The technical premise of TumorSight Risk is to extract information already present in the exam
\nthat a conventional report does not quantify. According to the company, its spatial AI modelling
\ncombines tumour characteristics with the context of surrounding tissue and clinical factors to
\nderive the score.<\/p>\n
That matters because risk stratification in HR+\/HER2- breast cancer is currently dominated by
\ntissue-based genomic signatures \u2014 assays that require a sample, shipping to a central laboratory,
\nsignificant cost and turnaround time. An alternative derived from an exam that has already been
\nperformed changes the logistics: no additional procedure, no tissue shipment, no specialised
\nhardware. Its weight therefore comes less from standalone accuracy and more from where it sits in
\nthe workflow.<\/p>\n
The evidence submitted<\/h2>\n
Clearance was supported by a blinded, retrospective, multi-institutional validation study of
\n2,129 patients, with participating sites including Mayo Clinic, Emory and Stanford. In findings
\npresented at the American Society of Clinical Oncology (ASCO) conference earlier in 2026,
\nresearchers reported that each 10-point increase in the score was associated with a 22% increase in
\nrecurrence risk.<\/p>\n
The submission also included a precision study in which 119 of 120 images processed successfully,
\nwith 99.4% agreement across replicate runs, and a human factors study in which 30 physicians and
\nstaff completed all critical tasks. The product builds on TumorSight Viz, the company’s previously
\ncleared surgical visualisation platform.<\/p>\n
What 510(k) clearance means \u2014 and what it does not<\/h2>\n
The regulatory mechanism deserves explaining, because it is routinely misread. The 510(k) pathway
\ndemonstrates substantial equivalence to a device already on the market; it is not an approval based
\non a prospective clinical trial with a survival endpoint. What was assessed is analytical performance
\nand equivalence, not proven clinical benefit in real-world use.<\/p>\n
In practice that defines the tool’s place: it is a prognostic aid to be weighed alongside other For the radiologist, the most immediate practical effect is not on the report but on exam There is also a workflow consequence: this class of tool pulls radiology closer to the oncology Three limitations stand out. The first is the population: HR+\/HER2- stage I to IIIA is a large but It is also worth remembering how crowded breast risk prediction has become. Models that read risk The real test will be head-to-head comparison against established genomic signatures in
\nclinicopathologic factors, not a replacement for the treatment decision. Anyone running breast
\nprotocols already knows this distinction from other contexts \u2014 it is the same logic we discussed
\nwhen we showed that
\ndetection and risk models are not interchangeable<\/a>.<\/p>\nWhat it means for imaging department routine<\/h2>\n
\nquality. Once MRI feeds a prognostic model, acquisition standardisation stops being a preference and
\nbecomes a requirement: consistent dynamic contrast-enhanced protocol, stable temporal resolution,
\nreproducible positioning and intact DICOM metadata. Variation between scanners and between protocols
\nis the main enemy of any imaging model, and departments already managing
\nbreast MRI screening protocols for dense breasts<\/a>
\nknow how much work that takes.<\/p>\n
\ndecision, which requires a new conversation with breast surgery and medical oncology about who
\norders it, who interprets it and where the score is recorded. That is not a software problem.<\/p>\nCautions before generalising<\/h2>\n
\nspecific slice, and nothing in the submission licenses extrapolation to triple-negative or
\nHER2-positive disease. The second is the retrospective nature of the validation \u2014 the sample is
\nrobust, but it does not answer whether the score changes management or improves outcomes. The third
\nis the first-of-its-kind claim: “first MRI-derived prognostic software” is a company statement
\nrepeated by trade press, not an independently verified fact.<\/p>\n
\nfrom mammography have already shown the ability to anticipate diagnoses over long horizons, as we
\ncovered in
\nAI flags breast cancer risk a decade early<\/a>,
\nand new breast imaging AI clearances have been frequent \u2014 the most recent being the
\nclearance of AI for breast ultrasound<\/a>.
\nWhat distinguishes TumorSight Risk is not predicting risk: it is predicting recurrence after
\ndiagnosis, a different clinical problem with a different audience and a different consequence.<\/p>\nWhat to watch over the coming months<\/h2>\n
\nindependent cohorts, not merely the association between score and recurrence. The question an
\noncologist will ask is concrete: in how many cases does the imaging score agree with the genomic
\nassay and, when they disagree, which one is right? Until that answer exists, the tool is likely to
\noccupy a complementary role \u2014 useful for triage and for cases where tissue assays are unavailable,
\nbut not yet a substitute.<\/p>\n